Leah L Zullig1, Kellie J Sims2, Rebecca McNeil2, Christina D Williams2, George L Jackson1, Dawn Provenzale2, Michael J Kelley3. 1. Center for Health Services Research in Primary Care, Durham Veterans Affairs Health Care System, 508 Fulton Street, Durham, NC 27705. 2. Cooperative Studies Program Epidemiology Center, Durham Veterans Affairs Health Care System, 508 Fulton Street, Durham, NC 27705. 3. Division of Medical Oncology, Duke University Medical Center, 2301 Erwin Road, Durham, NC 27710.
Abstract
INTRODUCTION: Nearly 50,000 incident cancer cases are reported in Veterans Affairs (VA) Central Cancer Registry (VACCR) annually. This article provides an updated report of cancer incidence recorded in VACCR. MATERIALS AND METHODS: Data were obtained from VACCR for incident cancers diagnosed in the VA health care system, focusing on 2010 data. Cancer incidence among VA patients is described by anatomical site, sex, race, stage, and geographic location, and was compared to the general U.S. cancer population. RESULTS: In 2010, among 46,170 invasive cancers, 97% were diagnosed among men. Approximately 80% of newly diagnosed patients were white, 19% black, and less than 2% were other minority races. Median age at diagnosis was 65 years. The three most frequently diagnosed cancers among VA were prostate (29%), lung/bronchus (18%), and colon/rectum (8%). Melanoma and kidney/renal pelvis tied for fourth (4%), and urinary bladder tied for sixth with liver and intrahepatic bile duct (3.4%). Approximately 23% of prostate, 21% of lung/bronchus, and 31% of colon/rectum cancers were diagnosed with Stage I disease. The overall invasive cancer incidence rate among VA users was 505.8 per 100,000 person-years. CONCLUSIONS: Although the composition of the VA population is shifting and includes a larger number of women, registry data indicate that incident cancers in VA in 2010 were most similar to those observed among U.S. men. Consistent reporting of VACCR data is important to provide accurate estimates of VA cancer incidence. This information can be used to plan efforts to improve quality of cancer care and access to services. Reprint &
INTRODUCTION: Nearly 50,000 incident cancer cases are reported in Veterans Affairs (VA) Central Cancer Registry (VACCR) annually. This article provides an updated report of cancer incidence recorded in VACCR. MATERIALS AND METHODS: Data were obtained from VACCR for incident cancers diagnosed in the VA health care system, focusing on 2010 data. Cancer incidence among VA patients is described by anatomical site, sex, race, stage, and geographic location, and was compared to the general U.S. cancer population. RESULTS: In 2010, among 46,170 invasive cancers, 97% were diagnosed among men. Approximately 80% of newly diagnosed patients were white, 19% black, and less than 2% were other minority races. Median age at diagnosis was 65 years. The three most frequently diagnosed cancers among VA were prostate (29%), lung/bronchus (18%), and colon/rectum (8%). Melanoma and kidney/renal pelvis tied for fourth (4%), and urinary bladder tied for sixth with liver and intrahepatic bile duct (3.4%). Approximately 23% of prostate, 21% of lung/bronchus, and 31% of colon/rectum cancers were diagnosed with Stage I disease. The overall invasive cancer incidence rate among VA users was 505.8 per 100,000 person-years. CONCLUSIONS: Although the composition of the VA population is shifting and includes a larger number of women, registry data indicate that incident cancers in VA in 2010 were most similar to those observed among U.S. men. Consistent reporting of VACCR data is important to provide accurate estimates of VA cancer incidence. This information can be used to plan efforts to improve quality of cancer care and access to services. Reprint &
Authors: Avo Artinyan; Sonia T Orcutt; Daniel A Anaya; Peter Richardson; G John Chen; David H Berger Journal: Ann Surg Date: 2015-03 Impact factor: 12.969
Authors: Apar K Ganti; Wilson Gonsalves; Fausto R Loberiza; Ibrahim Aldoss; Rishi Batra; Peter T Silberstein; Shanmuga P Subbiah; Anne Kessinger Journal: Am J Clin Oncol Date: 2016-04 Impact factor: 2.339
Authors: Rafael Santana-Davila; Kiran Devisetty; Aniko Szabo; Rodney Sparapani; Carlos Arce-Lara; Elizabeth M Gore; Amy Moran; Christina D Williams; Michael J Kelley; Jeffrey Whittle Journal: J Clin Oncol Date: 2014-11-24 Impact factor: 44.544
Authors: George L Jackson; L Douglas Melton; David H Abbott; Leah L Zullig; Diana L Ordin; Steven C Grambow; Natia S Hamilton; S Yousuf Zafar; Ziad F Gellad; Michael J Kelley; Dawn Provenzale Journal: J Clin Oncol Date: 2010-06-01 Impact factor: 44.544
Authors: Ted A Skolarus; Stephanie Chan; Jeremy B Shelton; Anna Liza Antonio; Anne E Sales; Jennifer L Malin; Christopher S Saigal Journal: Cancer Date: 2013-07-30 Impact factor: 6.860
Authors: Min-Woong Sohn; Huiyuan Zhang; Noreen Arnold; Kevin Stroupe; Brent C Taylor; Timothy J Wilt; Denise M Hynes Journal: Popul Health Metr Date: 2006-07-06
Authors: Andrew A Borkowski; Catherine P Wilson; Steven A Borkowski; L Brannon Thomas; Lauren A Deland; Stefanie J Grewe; Stephen M Mastorides Journal: Fed Pract Date: 2019-10
Authors: Shria Kumar; David C Metz; Gregory G Ginsberg; David E Kaplan; David S Goldberg Journal: Aliment Pharmacol Ther Date: 2020-03-04 Impact factor: 8.171
Authors: Jessie Torgersen; Tamar H Taddei; Lesley S Park; Dena M Carbonari; Michael J Kallan; Kisha Mitchell Richards; Xuchen Zhang; Darshana Jhala; Norbert Bräu; Robert Homer; Kathryn D'Addeo; Rajni Mehta; Melissa Skanderson; Farah Kidwai-Khan; Amy C Justice; Vincent Lo Re Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-10-01 Impact factor: 4.254
Authors: Leah L Zullig; Karen M Goldstein; Kellie J Sims; Christina D Williams; Michael Chang; Dawn Provenzale; Michael J Kelley Journal: J Womens Health (Larchmt) Date: 2018-06-19 Impact factor: 2.681
Authors: Maren T Scheuner; Kenute Myrie; Jane Peredo; Lori Hoffman-Hogg; Margaret Lundquist; Stephanie L Guerra; Douglas Ball Journal: Fed Pract Date: 2020-08